Announcements

  • December 31, 2011

    J. Taylor HardenDr. J Taylor Harden, who led efforts at NIA and in the research community nationwide to bring diversity to research and to the ranks of scientists conducting research on aging, retired from NIA on December 31. Since 1997, Dr. Harden was the Chief of the Office of Special Populations and the Assistant to the Director for Special Populations. In this capacity, she was responsible for activities supporting women, racially and ethnically diverse populations and disabled scientists; providing the NIA director and senior staff with advice and guidance on enhancing the participation of special populations in aging research initiatives; and providing guidance on NIA goals for research and training programs for special populations.

    “Taylor is known for her commitment to the development and support of researchers new to the field of aging research,” says Dr. Richard J. Hodes, NIA Director. “She has brought a diverse group of talented researchers into science through a dedication to mentoring and by understanding and providing the types of support that were needed.”

    As one strategy for recruiting and mentoring, Dr. Harden facilitated the NIA Grants Technical Assistance Workshop in conjunction with the annual meeting of the Gerontological Society of America. More than 600 participants attended the workshop between 1997 and 2011.

    The NIA Summer Institute on Aging Research, which marked its 25th anniversary in 2011, was a particularly special endeavor for Dr. Harden. Each year, she brought together new and early career scientists in aging research for a 7-day educational training curriculum that featured senior scientists from NIA staff and grantees. More than 1,000 investigators are graduates of the Summer Institute and many have gone on to distinguished careers in the field of aging research.

    Before coming to NIA, Dr. Harden held positions at the National Institute for Nursing Research and at the University of Texas Health Science Center at San Antonio School of Nursing. She is a fellow of the Gerontological Society of America, the New York Academy of Medicine, and the American Academy of Nursing. In retirement she has transitioned to service as chief administrator of the John A. Hartford Building Academic Geriatric Nursing Capacity initiative administered through the American Academy of Nursing.

  • May 14, 2012

    'Alzheimer's Disease Research Summit 2012; Path to Treatment and Prevention. May 14-15, 2012, National Institutes of Health, Bethesda, MD.'The Alzheimer’s Disease Research Summit 2012: Path to Treatment and Prevention was held May 14-15, 2012.

    Webcast of the Summit is available here:

    Transcripts:

    The Summit was hosted by the Department of Health and Human Services and the National Institute on Aging at NIH, with private support through the Foundation for NIH.

    Location:
    Natcher Auditorium, Building 45
    National Institutes of Health
    Bethesda, MD, Campus
    NIH Map and Visitor Information

    Date & Time:
    Monday, May 14, 2012: 8 a.m. - 6 p.m.
    Tuesday, May 15, 2012: 8 a.m. - 1:40 p.m.

    Additional Public Comment through May 18:  COMMENT PERIOD IS CLOSED
    You may send your comments about the “Alzheimer’s Disease Research Summit 2012: Path to Treatment and Prevention” to niaadresearchsummit@mail.nih.gov until Midnight (Eastern Time), Friday May 18, 2012. Comments received by that date will be added to the final Summit transcript, which will be sent to the Secretary of HHS for her consideration along with the recommendations from the Summit.

    Check back for further details to be posted here and on the HHS/Assistant Secretary for Planning and Evaluation websites as they become available.

    Questions? E-mail niaadresearchsummit@mail.nih.gov

  • February 1, 2012

    Deposits of amyloid protein in the brain are considered a hallmark of Alzheimer’s disease. Now, for the first time, greater levels of cognitive activity—reading, writing, and playing games—have been associated with lower amyloid levels in the brains of cognitively healthy older people, according to NIA-supported research published online January 23 in the Archives of Neurology.

    Researchers at the University of California, Berkeley imaged the brains of 65 cognitively normal volunteers aged 60 and older using positron emission tomography (PET) and Pittsburgh Compound B (PiB), a tracer that binds to amyloid in the brain. The participants provided estimates of the frequency of their cognitive activities over their lifetimes and underwent neuropsychological testing of their memory and other cognitive functions. The researchers then compared the brain scans of these healthy older participants to brain scans of 10 volunteers with Alzheimer’s disease and to 11 cognitively healthy volunteers in their 20s.

    The researchers found a significant association between higher levels of mental stimulation over a lifetime and lower levels of amyloid in the brains of the healthy older volunteers. The relationship remained significant even when accounting for age, gender, and years of education. Other lifetime activities examined, such as current levels of cognitive activity, did not show an association with amyloid deposits. The results may suggest frequent engagement in cognitive activity in early and mid-life might help to delay or prevent the abnormal levels of amyloid in the brain, which accompany Alzheimer’s disease in later life. The NIA and the Alzheimer’s Association funded the study.

    Reference:

    Landau, S.M., et al. Association of lifetime cognitive engagement and low B-amyloid deposition. Archives of Neurology. Published online Jan. 23, 2012.

  • January 17, 2012

    2010 Alzheimer’s Disease Progress Report: A Deeper Understanding, the latest annual Alzheimer’s research report from the National Institutes of Health (NIH) , is now available online. Prepared by the National Institute on Aging, which leads the NIH effort conducting and supporting research on age-related cognitive decline and Alzheimer’s disease, the report highlights important developments and directions in NIH-funded research, including: risk for developing Alzheimer’s; genes that play a role in the disease; neuroimaging and biomarkers that detect and track the disease; research into new treatments; lifestyle factors that may worsen or protect against the disease; and help for caregivers. Special features include animation showing the progression of Alzheimer’s in the brain and video interviews highlighting new insights into the disease.

  • January 5, 2012

    While most Americans depend on heating and air conditioning systems to keep comfortable during winter and summer, the body itself is a master regulator of temperature. The nervous system regulates the body’s heat production and dissipation through the skin, causing us to shiver when we are too cold and sweat when we are too hot. However, the genetic mechanisms driving sweat secretion are still largely unknown.

    In the January 5, 2012 online issue of Proceedings of the National Academy of Sciences, investigators from NIA’s Laboratory of Genetics describe the first genetic cascade found to be involved in regulating sweat secretion. The scientists developed a strain of mice that lack FoxA1, a protein that controls when certain genes are activated, specifically in skin. They found that, while the mice did develop sweat glands, they did not sweat. This indicates that FoxA1 is involved in regulating sweat secretion. They also found evidence that two additional proteins, Best2 and NKcc1, were targets of FoxA1 and involved in the sweating process. The findings may provide future research direction for studying potential medicines that could protect against hyperthermia in extreme conditions, and alleviate reduced temperature regulation in older people.

    Reference: Cui C.Y., et al. Forkhead transcription factor FoxA1 regulates sweat secretion through Bestrophin 2 anion channel and Na-K-Cl cotransporter 1. PNAS USA January 5, 2012. Epub ahead of print.

  • January 16, 2012

    NIA and the World Health Organization (WHO) announce the availability of a new report, Global Health and Aging (PDF, 15.7M). As both the proportion of older people and the length of life increase throughout the world, key questions arise. Will population aging be accompanied by a longer period of good health, a sustained sense of well-being, and extended periods of social engagement and productivity, or will it be associated with more illness, disability, and dependency? How will aging affect health care and social costs? Are these futures inevitable, or can we act to establish a physical and social infrastructure that might foster better health and wellbeing in older age? How will population aging play out differently for low-income countries that will age faster than their counterparts have, but before they become industrialized and wealthy? This brief report, jointly issued by the WHO’s Department of Ageing and the Life Course and the NIA attempts to address some of these questions, emphasizing the central role that health will play in coming years.

  • January 10, 2012

    A nicotine skin patch may improve cognition in older people with mild cognitive impairment (MCI), a condition marked by memory loss that often leads to Alzheimer’s dementia, according to findings from a small pilot clinical trial reported in the Jan. 10, 2012 print issue of Neurology. Nearly 70 volunteers, all non-smokers, wore either a nicotine patch or a placebo patch during the six month trial supported by the NIH. Researchers measured the volunteers’ cognitive performance at the start, at three months and at the end of the trial. They found the nicotine group showed significantly improved cognition during tests of mental speed, attention, and memory, and that the nicotine patch was safe to use for the trial period.  Additionally, the nicotine group participants reported improved cognition, which was also noted by their caregivers.  While the results of this small pilot trial were promising, the findings are not definitive and further investigation of a nicotine patch treatment for MCI in larger studies is warranted. Paul Newhouse, M.D., now of Vanderbilt University School of Medicine, Nashville, TN, led the trial while at the University of Vermont College of Medicine. The study was supported by the National Institute on Aging and the National Institute of General Medical Sciences, both parts of NIH at the U.S. Department of Health and Human Services.

    Reference:

    Newhouse P., et al. Nicotine treatment of mild cognitive impairment: a six-month double-blind pilot clinical trial. Neurology January 10, 2012 78:91-101.

  • February 15, 2011

    The U.S. Department of Veterans Affairs (VA) is expanding support nationally to caregivers of veterans with Alzheimer’s disease with a program developed by NIA-funded researchers. The REACH VA (Resources for Enhancing Alzheimer’s Caregiver Health in VA) program is the first national clinical implementation of a proven behavioral intervention for caregiver burden and stress. Results of the original REACH program were published in 2006.

    REACH VA involved 127 caregivers connected to 24 VA medical centers. The median age for the caregiver was 72 and the majority of the participants were spouses. For 6 months, the REACH VA caregivers were provided with a number of options based on their needs: individual in-home and telephone counseling sessions; telephone support group sessions; a caregiver quick guide with 48 behavioral and stress topics; education on safety and patient behavior management; and training for their individual health and well-being.

    Caregivers for veterans with Alzheimer’s disease and dementia typically reported feeling overwhelmed, frustrated, cut off from family and friends, lonely, prone to bouts of crying and having worse physical health than the year before. After participating in the REACH VA program, caregivers reported their burden reduced; drops in depressive symptoms; fewer frustrations, including those that have potential for abuse; and decreases in dementia-related behaviors from the veterans they cared for. Caregivers also reported they were able to spend fewer hours per day devoted to caregiving duties.

    Reference:

    Nichols LO, Martindale-Adams J, Burns R, Graney MJ, Zuber J. Translation of a Dementia Caregiver Support Program in a Health Care System—REACH VA. Arch Intern Med. 2011;171(4):353-359.

  • February 19, 2011

    Parkinson’s disease, a progressive movement disorder, was historically considered a nongenetic disease. Now, in the largest genome-wide association study to date of Parkinson’s disease, scientists show genetics play a substantial role in the disease. They have identified five new genomic regions in people of European ancestry and confirmed six previously identified regions that may contribute to increased disease risk.

    The study, funded in part by the NIH, involved leading Parkinson’s research centers in the United States and Europe working together to pool DNA data from more than 33,000 participants. The researchers first scanned the genome to locate regions containing gene variants associated with Parkinson’s. To confirm these findings, they then looked for these suspect risk variants in DNA from an independent group of people with Parkinson’s or free of the disease. Based on these 11 risk variants, they found that those individuals who were in the top 20 percent in terms of genetic risk were more than two and a half times as likely to have the disease than those who were in the bottom 20 percent of the genetic risk spectrum.

     “Up until just 10 or 15 years ago, the field did not think genetics played much of a role in the development of Parkinson’s disease,” said Dr. Andrew Singleton, chief of NIA’s Laboratory of Neurogenetics and co-author of the study. “This work not only increases our understanding of how genes are involved in the disease process, but with more research, may one day result in the development of better diagnostics and therapeutic interventions for this debilitating disease.”

    Reference:

    International Parkinson Disease Genomics Consortium. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. 2011 Feb 19;377(9766):641-9. Epub 2011 Feb 1.

  • July 7, 2011

    The first results of the 2008 Oregon health insurance lottery study, supported in part by the NIA, indicate that people enrolled in the state’s Medicaid program reported improved health and well-being, as well as reduced financial strain. They also saw an increase in use of primary and preventive care as well as hospitalizations. Program expenditures rose as a result of the rise in utilization. The study results were reported in a National Bureau of Economic Research (NBER) Working Paper, in a collaboration between NBER researchers and the state of Oregon.

    The Oregon program randomly assigned 10,000 low-income uninsured adults to the state’s Medicaid program. Participants were chosen from about 90,000 people who signed up for the lottery program. After 1 year, the study found that enrollment in Medicaid increased the likelihood of using outpatient care by 35 percent, using prescription drugs by 15 percent, and having a regular office or clinic for primary health care by 70 percent among those with insurance. The probability of having an unpaid medical bill sent to a collection agency decreased by 25 percent among those in the program. The probability of people reporting themselves in good to excellent health (compared with fair or poor health) increased by 25 percent among those with insurance. The increased use of health care services resulted in an estimated 25 percent increase in annual health care expenditures.

    The researchers note that these findings are part of a broader study that will continue to follow the participants in the program. Ongoing work will provide more information on the effects of expanded insurance, including specific clinical indicators and health outcomes measured over 2 years; the current study covers the first year of the lottery. Together, this information will facilitate the evaluation of costs and benefits of insurance expansions.

    Reference:

    Finkelstein, A., et al. The Oregon Health Insurance Experiment: Evidence from the First Year, NBER Working Paper 17190, National Bureau of Economic Research, Cambridge, Mass., July 7, 2011. www.nber.org.

Pages